• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

CVM Being Dissolved

Quote

anonymous

Guest
Katie Devine destroyed CVM & Xarelto when she thought it was a good idea to stop calling on customers who were loyal for 10+ years to call on a primary care doctor who never started a patient on an AC.

JACI was as idiotic as thinking DEP is more valuable than reps knowing their customers and who to call on.

She ran the franchise into the dirt then parachuted to a new job leaving the reps who carried X to billions in sales left holding the bag.

Good riddance to her from CVM but CVM will end up being imploded due to the downward death spiral she began.
 




















anonymous said:
Katie Devine destroyed CVM & Xarelto when she thought it was a good idea to stop calling on customers who were loyal for 10+ years to call on a primary care doctor who never started a patient on an AC.

JACI was as idiotic as thinking DEP is more valuable than reps knowing their customers and who to call on.

She ran the franchise into the dirt then parachuted to a new job leaving the reps who carried X to billions in sales left holding the bag.

Good riddance to her from CVM but CVM will end up being imploded due to the downward death spiral she began.
Click to expand...
No Vanessa Broadhurst ruined CVM she did the same at Amgen and then she passed the shit show on to Katie who made it worst! But Katie leave and Vanessa gets promoted? Also, a parachute was afforded to JCP, NJPP and KT? that’s JNJ for ya!
 








anonymous said:
No Vanessa Broadhurst ruined CVM she did the same at Amgen and then she passed the shit show on to Katie who made it worst! But Katie leave and Vanessa gets promoted? Also, a parachute was afforded to JCP, NJPP and KT? that’s JNJ for ya!
Click to expand...
Vanessa Broadhurst was a bad choice the first time around, then they brought her back for Xarelto, followed by more than a few abysmal leadership choices.
 




anonymous said:
No Vanessa Broadhurst ruined CVM she did the same at Amgen and then she passed the shit show on to Katie who made it worst! But Katie leave and Vanessa gets promoted? Also, a parachute was afforded to JCP, NJPP and KT? that’s JNJ for ya!
Click to expand...
How do all these people keep getting promoted?!?! JACI, DEP is the worst program I’ve ever seen in Pharma! Coming from people who have NEVER stood toe to toe with a cardiologist. And to think a PCP could drive DOAC business is hilarious! And the Eliquis reps just keep on laughing at us! Yesterday was the best thing that could have happened to me! Thx CREDO! Hope the ceo enjoys his 117% pay increase while we collect unemployment!
 








So hilarious to see Foody on LinkedIn talking about the future of CV and Pulmonary with JnJ. And touting the ridiculous CREDO! Where is the credo when layoffs happen. Where is the credo when folks can’t afford their meds. Where is the credo when I’m told that physician is not profitable, so don’t waste time or resources on him. Where is the credo when the ceo gets a 117% salary increase ahead of waves of people being told their aren’t relevant anymore! JnJ should be ashamed. Awful!
 




The most piss poor leadership at all places over at CVM. Embarrassing the way all of this has been handled. The worst part is the fact that some of these DMs will get another role even though they’ve lost so much great talent the last few years.
 




anonymous said:
Katie Devine destroyed CVM & Xarelto when she thought it was a good idea to stop calling on customers who were loyal for 10+ years to call on a primary care doctor who never started a patient on an AC.

JACI was as idiotic as thinking DEP is more valuable than reps knowing their customers and who to call on.

She ran the franchise into the dirt then parachuted to a new job leaving the reps who carried X to billions in sales left holding the bag.

Good riddance to her from CVM but CVM will end up being imploded due to the downward death spiral she began.
Click to expand...
Katie had a lot of help for the last 10 years. Calvin Schmidt decided to pull reps out of the institutions at a critical time in the life cycle. This, despite strong concerns and warnings from those who actually know the markets. Amazing that there is no accountability in these leadership teams.
The rotating door of marketing geniuses who had no experience in marketing that led to quarterly or semi-annual marketing message changes for the past several years did this product no favors. Xarelto became a stop on their way to move up in the company - results be damned.
How about the medical affairs team who refused to acknowledge or understand market affects of renal patient information? The company also underestimated the competition who have been working with and entrenched in cardiology organizations for decades.
Apparently, J&J hasn't met a vender they don't like so leaders have been talked into programs that also did not serve customers. In fact, they often alienated many of them - JACI, DEP, and limits to who are called upon by field.
Finally, the increased importance of data and metrics by people who didn't understand the whole picture. Applying metrics to institution and medical affairs was ridiculous and shows the decision-makers have no idea what those folks do.
No one was watching this store for a long time. Katie may not have helped but she just continued a long sad track record of poor decisions.
 




anonymous said:
Katie had a lot of help for the last 10 years. Calvin Schmidt decided to pull reps out of the institutions at a critical time in the life cycle. This, despite strong concerns and warnings from those who actually know the markets. Amazing that there is no accountability in these leadership teams.
The rotating door of marketing geniuses who had no experience in marketing that led to quarterly or semi-annual marketing message changes for the past several years did this product no favors. Xarelto became a stop on their way to move up in the company - results be damned.
How about the medical affairs team who refused to acknowledge or understand market affects of renal patient information? The company also underestimated the competition who have been working with and entrenched in cardiology organizations for decades.
Apparently, J&J hasn't met a vender they don't like so leaders have been talked into programs that also did not serve customers. In fact, they often alienated many of them - JACI, DEP, and limits to who are called upon by field.
Finally, the increased importance of data and metrics by people who didn't understand the whole picture. Applying metrics to institution and medical affairs was ridiculous and shows the decision-makers have no idea what those folks do.
No one was watching this store for a long time. Katie may not have helped but she just continued a long sad track record of poor decisions.
Click to expand...
When the representatives were taken out of the institutions was definitely the start of the downfall. I was a PCP rep and remember telling my manager this would be a devastating move. They were more concerned with us filling out the weekly “How may scripts did you get“ than listening to our concerns. The reps were kept out of institutions for over a year. We never recovered.
 




When the representatives were taken out of the institutions was definitely the start of the downfall. I was a PCP rep and remember telling my manager this would be a devastating move. They were more concerned with us filling out the weekly “How may scripts did you get“ than listening to our concerns. The reps were kept out of institutions for over a year. We never recovered.
 




anonymous said:
Katie had a lot of help for the last 10 years. Calvin Schmidt decided to pull reps out of the institutions at a critical time in the life cycle. This, despite strong concerns and warnings from those who actually know the markets. Amazing that there is no accountability in these leadership teams.
The rotating door of marketing geniuses who had no experience in marketing that led to quarterly or semi-annual marketing message changes for the past several years did this product no favors. Xarelto became a stop on their way to move up in the company - results be damned.
How about the medical affairs team who refused to acknowledge or understand market affects of renal patient information? The company also underestimated the competition who have been working with and entrenched in cardiology organizations for decades.
Apparently, J&J hasn't met a vender they don't like so leaders have been talked into programs that also did not serve customers. In fact, they often alienated many of them - JACI, DEP, and limits to who are called upon by field.
Finally, the increased importance of data and metrics by people who didn't understand the whole picture. Applying metrics to institution and medical affairs was ridiculous and shows the decision-makers have no idea what those folks do.
No one was watching this store for a long time. Katie may not have helped but she just continued a long sad track record of poor decisions.
Click to expand...
pCp shill hear so do I still get the Volvo sales wagon charriott shill mobile Tuesday?
 




anonymous said:
When the representatives were taken out of the institutions was definitely the start of the downfall. I was a PCP rep and remember telling my manager this would be a devastating move. They were more concerned with us filling out the weekly “How may scripts did you get“ than listening to our concerns. The reps were kept out of institutions for over a year. We never recovered.
Click to expand...
When fleet kept out the VOLVOs over a year ago We never recovered.
 
















Top Bottom
Back
Quote